眼瞼炎治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Blepharitis - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0873
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Blepharitis – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis – Pipeline Review, H1 2020, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.

Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid’s oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Blepharitis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 7 respectively.

Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Blepharitis – Overview
Blepharitis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Blepharitis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Blepharitis – Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
Azura Ophthalmics Ltd
Formosa Pharmaceuticals Inc
Hovione FarmaCiencia SA
Merck & Co Inc
NicOx SA
Novaliq GmbH
Premark Pharma GmbH
Quorum Innovations LLC
Surface Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
Blepharitis – Drug Profiles
(doxycycline + omega 3 fatty acid) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-13002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZRBL-007 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZRBL-008 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-02 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-03 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMP-2207 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qi-402 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Dry Eye and Meibomian Blepharitis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-03 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Blepharitis – Dormant Projects
Blepharitis – Product Development Milestones
Featured News & Press Releases
Dec 19, 2019: Nicox’s NCX 4251 meets primary endpoint in phase 2 blepharitis trial and shows promising efficacy in dry eye disease
Sep 27, 2019: Nicox completes enrolment of NCX 4251 phase 2 trial with top-line results on track for Q4 2019
Mar 19, 2019: Nicox initiates phase 2 trial of NCX 4251 in Blepharitis
Mar 18, 2019: Nicox poster presentation at AGS 2019 Annual Meeting Discloses preclinical data for NCX 4251, a novel blepharitis therapy
Mar 12, 2019: Nicox announces presentations including drug candidate NCX 4251 at upcoming scientific conferences
Jan 29, 2019: Nicox announces U.S. FDA acceptance of Investigational New Drug Application for NCX 4251 phase 2 trial in Blepharitis
Jan 05, 2017: Nicox provides clinical and regulatory update for NCX 4251 in blepharitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Blepharitis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Blepharitis - Pipeline by Aerie Pharmaceuticals Inc, H1 2020
Blepharitis - Pipeline by Azura Ophthalmics Ltd, H1 2020
Blepharitis - Pipeline by Formosa Pharmaceuticals Inc, H1 2020
Blepharitis - Pipeline by Hovione FarmaCiencia SA, H1 2020
Blepharitis - Pipeline by Merck & Co Inc, H1 2020
Blepharitis - Pipeline by NicOx SA, H1 2020
Blepharitis - Pipeline by Novaliq GmbH, H1 2020
Blepharitis - Pipeline by Premark Pharma GmbH, H1 2020
Blepharitis - Pipeline by Quorum Innovations LLC, H1 2020
Blepharitis - Pipeline by Surface Pharmaceuticals Inc, H1 2020
Blepharitis - Pipeline by Tarsus Pharmaceuticals Inc, H1 2020
Blepharitis - Dormant Projects, H1 2020

【掲載企業】

Aerie Pharmaceuticals Inc
Azura Ophthalmics Ltd
Formosa Pharmaceuticals Inc
Hovione FarmaCiencia SA
Merck & Co Inc
NicOx SA
Novaliq GmbH
Premark Pharma GmbH
Quorum Innovations LLC
Surface Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[眼瞼炎治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆